Quand débuter les antirétroviraux? Recommandations internationales Formation à l’usage des antirétroviraux Pr Willy Rozenbaum When to Start Antiretroviral Therapy Potential Benefits of Early Therapy Earlier suppression of viral replication Preservation of immune function Prolongation of disease-free survival Lower risk of virologic failure? Lower risk of detrimental viral evolution Possible decrease in the risk of HIV transmission clinicaloptions.com/hiv When to Start Antiretroviral Therapy CD4+ Cell Count Response Based on Baseline CD4+ Cell Count Mean CD4+ Cell Count (cells/mm3) Johns Hopkins HIV Clinical Cohort ATHENA National Cohort 1000 1000 800 800 600 600 400 400 BL CD4 > 350 201-350 < 200 200 0 0 1 2 3 Years on HAART Keruly J, et at. CROI 2006. Abstract 529. Gras L, et al. CROI 2006. Abstract 530. 4 BL CD4 201-350 > 500 51-200 351-500 < 50 200 0 5 0 48 96 144 192 240 288 336 Weeks From Starting HAART clinicaloptions.com/hiv When to Start Antiretroviral Therapy HAART and Survival Based on Initial CD4+ Cell Count Modeled data from ART Cohort Collaborative 10,855 patients included 934 progressed to AIDS or died IDUs censored from model Progression and Death According to CD4+ Cell Count (cells/mm3) < 200 vs 201-350 < 350 vs 351-500 Hazard ratio for AIDS (95% CI) 3.68 (3.01-4.51) 1.52 (1.10-2.10) Hazard ratio for AIDS or death (95% CI) 2.93 (2.41-3.57) 1.26 (0.94-1.68) Cumulative Probability of AIDS/Death According to CD4+ Cell Count at Initiation of HAART 0.14 Probability of AIDS or Death 101-200 cells/mm3 201-350 cells/mm3 351-500 cells/mm3 0.12 0.10 0.08 0.06 0.04 0.02 0.00 0 1 2 3 4 5 Years Since Initiation of HAART D’Arminio Monforte A, et al. CROI 2006. Abstract 525. clinicaloptions.com/hiv When to Start Antiretroviral Therapy Time to Virologic Failure Stratified by Baseline CD4+ Cell Count Patients Responding (%) 100 80 60 Baseline CD4+ cell count (cells/mm3) < 200 (n = 331) 200 to < 350 (n = 345) 350 to < 500 (n = 302) 500 (n = 236) 40 20 0 0 12 24 36 48 60 72 84 96 Time Since Start of Treatment (Weeks) Levy RS, et al. CROI 2001. Poster 325. clinicaloptions.com/hiv When to Start Antiretroviral Therapy Increasing Prevalence of X4- or R5/X4Tropic Virus at Lower CD4+ Cell Counts CCR5 CXCR4 – With advanced disease, X4- or dual-tropic virus emerges – Associated with more rapid clinical and immunologic progression Could CCR5 inhibition select for more virulent X4-tropic virus? Moyle G, et al. ICAAC 2004. Abstract 1135. Prevalence of X4 or R5/X4 (%) – Patients with early-stage HIV disease tend to have pure R5tropic virus 100 80 60 41.9% 40.0% 51-100 < 50 40 20 16.0% 16.0% 14.8% 0 > 300 201-300 101-200 CD4+ Cell Count (cells/mm3) n= 248 104 81 31 50 clinicaloptions.com/hiv Prise en charge médicale des personnes infectées par le VIH – Rapport 2006 • Traitement antirétroviral (1) Quand débuter un traitement antirétroviral ? Situation Recommandation Patients symptomatiques Initiation le plus rapidement possible, en tenant (Stades C et B avec symptômes compte du traitement de l’infection opportuniste marqués) et des interactions médicamenteuses éventuelles Patients asymptomatiques avec CD4 < 200/mm3 Initiation sans délai Patients asymptomatiques avec CD4 < 350/mm3 Initiation, sauf si arguments individuels pour différer Patients asymptomatiques avec CD4 > 350/mm3 Initiation habituellement non recommandée, envisageable dans certaines circonstances (CV > 100 000 c/ml…) • L'instauration d'un traitement ARV doit toujours être préparée – Travail multidisciplinaire pour optimiser l’adhésion au traitement et aux soins DHHS Guidelines: When To Start 2008 Clinical Conditions and/or CD4 Count Recommendations History of AIDS-defining Illness CD4 count <350 cells/mm3 Pregnant women Persons with HIV-associated nephropathy Persons coinfected with HBV, when HBV treatment is indicated Initiate ARV Therapy Patients with CD4 > 350 cells/mm3 Optimal time to initiate ARV therapy not well defined Consider patient scenarios and comorbidities